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ABSTRACT Quantitative bacterial culture of bronchoalveolar lavage fluids (BALF) is
labor-intensive, and the delay involved in performing culture, definitive identifica-
tion, and susceptibility testing often results in prolonged use of broad-spectrum an-
tibiotics. The Unyvero lower respiratory tract (LRT) panel (Curetis, Holzgerlingen, Ger-
many) allows the multiplexed rapid detection and identification of 20 potential
etiologic agents of pneumonia within 5 h of collection. In addition, the assay in-
cludes detection of gene sequences that confer antimicrobial resistance. We retro-
spectively compared the performance of the molecular panel to routine quantitative
bacterial culture methods on remnant BALF. Upon testing 175 BALF, we were able
to analyze positive agreement of 181 targets from 129 samples, and 46 samples
were negative. The positive percent agreement (PPA) among the microbial targets
was 96.5%, and the negative percent agreement (NPA) was 99.6%. The targets with
a PPA of 100% were Staphylococcus aureus (34/37 [91.9%]), Streptococcus pneu-
moniae (10/11 [90.9%]), and Enterobacter cloacae complex (2/4 [50%]). For the ana-
lyzable resistance targets, concordance with phenotypic susceptibility testing was
79% (14/18). This study found the Unyvero LRT panel largely concordant with cul-
ture results; however, no outcome or clinical impact studies were performed.
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Lower respiratory tract infections (LRTI) present with a wide variety of symptoms,severity, and causative agents. Therefore, a wide range of diagnostic methods is
needed to detect and differentiate bacterial, viral, and fungal causative agents of LRTI,
including quantitative bacterial culture, direct staining, and molecular methods. Cases
of pneumonia can be partitioned into community-acquired pneumonia (CAP), hospital-
acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and health care-
associated pneumonia (HCAP) cases. Diagnostic and treatment guidelines for CAP have
been well characterized, perhaps due to the comparative simplicity of disease presen-
tation and the improved clinical outcomes observed (1). More complex, however, are
recommendations for cases in which the patient is hospitalized or has long-term
contact with the health care setting. It has been hypothesized that prolonged health
care exposure can lead to colonization and microaspiration of multidrug-resistant
organisms, presenting the opportunity for more severe infections with limited thera-
peutic options (2).
Multiplexed syndromic panels, such as the one evaluated in this study, can rapidly
provide diagnostic details that help inform best management practices in complex
cases of pneumonia. This study aimed to evaluate the performance of the Unyvero LRT
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TABLE 1 Organisms and resistance markers included on the IUO LRT panela
Organism or resistance marker Target(s)
Organism type
Gram-positive bacteria Staphylococcus aureus*, Streptococcus pneumoniae*
Enterobacterales Citrobacter freundii*, Escherichia coli*, Enterobacter cloacae complex*, Proteus spp.*,
Klebsiella pneumoniae*, Klebsiella oxytoca*, Klebsiella variicola*, Serratia marcescens*, Morganella morganii*
Nonfermenters Acinetobacter baumannii complex*, Stenotrophomonas maltophilia*, Legionella pneumophila*,
Pseudomonas aeruginosa*
Others Pneumocystis jirovecii*,b Haemophilus influenzae*, Mycoplasma pneumoniae*, Chlamydia pneumoniae*,
Moraxella catarrhalis*
Resistance type
Macrolide/lincosamide ermB
Oxacillin mecA*, mecC (LGA251)
Penicillin blaTEM*, blaSHV
Third-generation cephalosporin blaCTX-M*
Carbapenem blaKPC*, blaIMP, blaNDM*, blaOXA-23*, blaOXA-24/40*, blaOXA-48*, blaOXA-58*, blaVIM*
Sulfonamide sul-1
Fluoroquinolone (E. coli and
P. aeruginosa only)
gyrA83, gyrA87
a*, target included on the FDA-cleared LRT panel.
bBALF only.
panel (Curetis; Holzgerlingen, Germany), compared to quantitative bacterial culture
performed as a part of routine diagnostics in the clinical laboratory.
MATERIALS AND METHODS
Study design. Bronchoalveolar lavage fluid (BALF) specimens were submitted to the University of 
North Carolina Hospitals’ clinical microbiology laboratory for routine bacterial testing to include Gram 
staining and quantitative bacterial culture with antimicrobial susceptibility testing (AST) based on 
standard laboratory procedures (below). Specimens from cystic fibrosis patients and patients 16 years 
old were excluded. Specimens (n  175) from 98 patients included 67 patients with one sample each and 
31 patients with two to eight specimens each. Multiple aliquots of remnant BALFs were frozen at 70°C 
within 24 h of collection. Specimens were thawed prior to testing with the Unyvero instrument and were 
tested an average of 27 days after collection (median, 9 days; range, 1 to 188 days).
Following guideline recommendations, when pathogens present in culture at quantities less than 
10,000 CFU/ml were not detected by PCR, results were considered true negative (3, 4). Medical records 
were reviewed to investigate potential sources of bacterial DNA in cases where a pathogen was detected 
by PCR and not isolated by culture. If a patient’s sample had grown the detected organism within 40 days 
of collection of the discordant sample, results were considered true positive. If culture results included 
mixed growth or overgrowth of an organism (defined as 400,000 CFU/ml), any detections that were not 
found in culture were not considered false positive, and instead targets were given the label “unable to 
analyze concordance.”
Culture methods. BALF specimens were collected as part of routine clinical care and transported to 
the laboratory in sterile screw-cap containers. Gram stains were made using 100 l of sample. All 
specimens were plated directly to buffered charcoal yeast extract agar and diluted 1:100, and 100 l was 
plated to chocolate, colistin-nalidixic acid, and MacConkey agars (BD Diagnostics, Sparks, MD). Plates 
were examined at 24, 48, and 96 h of incubation. A mixture of two or more members of the oropha-
ryngeal microbiota with no predominating pathogens was given the result “oropharyngeal flora present” 
(OPF). In a case where there was a predominating organism, it was identified via matrix-assisted laser 
desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (Vitek MS; bioMérieux, Durham, 
NC) and reported quantitatively, along with antimicrobial susceptibility results obtained by disk diffusion 
using Clinical and Laboratory Standards Institute breakpoints (5). If fewer than 10,000 organisms per ml 
were present, the report read “10,000 CFU/ml.” In cases where three or more organisms were equally 
present, the laboratory reported “mixed organisms present” along with a summary of the Gram stain 
characteristics (e.g., “mixed Gram-positive organisms present”). The predominant pathogen from a 
culture with three or more organisms was identified by MS and underwent phenotypic AST; the 
remaining organisms were reported as mixed.
Unyvero testing. The investigational-use-only (IUO) version of the Unyvero LRT panel was used 
according to the manufacturer’s instructions. Organism and resistance gene targets of the IUO LRT panel 
are shown in Table 1, along with the FDA-cleared targets. The in vitro diagnostic version of the LRT panel 
is FDA cleared for tracheal aspirates and bronchoalveolar lavage samples (BALF and mini-BALF). BALF 
specimens were kept at  70°C and thawed at room temperature immediately prior to testing. 
The provided sample tubes were inoculated with 180  l of sample and loaded onto the instrument 
for a 30-minute lysis before being inserted into the provided cartridge for a 4.5-h PCR and detection 
step. The stated limit of detection for this assay is 10,000 CFU/ml.
This study was approved by the University of North Carolina at Chapel Hill Institutional Review Board.
Discordant analysis. Discrepant microorganism results between quantitative culture and the LRT 
panel were analyzed by analyte-specific singleplex PCRs followed by bidirectional sequencing. DNA was 
extracted from a unique frozen BALF aliquot using the QIAamp DNA blood minikit (Qiagen, Germantown, 
MD). Analyte-specific PCRs with two different proprietary primer pairs (Unyvero primers and a second 
primer set) for each observed discrepant analyte were performed on extracted specimen DNA by Curetis. 
In general, the 23S rRNA gene was targeted for most pathogens; other targets included rpoB for Klebsiella 
pneumoniae and Enterobacter cloacae, psaA and lyt for Streptococcus pneumoniae and copB for Moraxella 
catarrhalis. Amplified products were bidirectionally sequenced at an external service provider (Mi-
crosynth, Balgach, Switzerland). Identity of aligned consensus sequences was confirmed by BLAST 
analysis. Any discrepant analyte that could not be amplified or could not be confirmed by sequencing 
was considered not present in the analyzed specimen.
RESULTS
Among the 98 patients tested, the mean and median ages were 55 and 58, 
respectively, with 45% being 60 years old. Samples were obtained from patients in a 
variety of clinical settings: 33% from the medical or surgical intensive care unit (ICU), 
31% from the burn ICU, and 25% from other inpatient or ICU settings; only 11% were 
outpatients. Samples were partitioned into three groups based on the complexity of 
the results (low, medium, and high) for the purpose of discussion.
Among the 175 samples tested, culture results (n  61) included either no growth, 
OPF not further identified, or growth of a pathogen that was not on the LRT panel 
(Candida spp., n  7; Burkholderia spp., n  5; three each of Corynebacterium spp. and 
Mycobacterium spp.; two each of Aspergillus spp., coagulase-negative Staphylococcus, 
Enterococcus spp., Klebsiella aerogenes, Neisseria meningitidis, Nocardia spp.; one each of 
Achromobacter sp., Providencia stuartii, Raoultella ornithinolytica, Streptococcus dysga-
lactiae, and Streptococcus mitis). For the 61 low-complexity-group specimens listed 
above, Unyvero was negative (n  45), detected a pathogen that had been isolated 
from the patient in the previous 40 days (n  11), or detected a pathogen considered 
to be a false positive (n  5). Of the 11 samples where a pathogen had been detected 
in the previous 40 days, in which 12 distinct organisms were detected by Unyvero, all 
patients had been start on antibiotic therapy 12 h prior to collection. The remaining 
samples (n  5) in this group had six false-positive detections. Discrepant analysis by 
sequencing revealed that all but one detection of S. aureus were true positives. Results 
for this low-complexity group of samples before and after discrepant analysis are 
shown in Table S1 in the supplemental material.
A group of medium-complexity samples (n  73) were positive for one or more 
pathogens on the LRT panel. These samples (n  73) had 102 true positive detections 
and two false-positive detections. Sequencing confirmed the presence of both organ-
isms in the initial false-positive samples. In three samples, Unyvero missed detections. 
Sequencing confirmed the presence of the organisms for two of these false negatives; 
further investigation was not performed for one S. aureus false negative, since the 
culture was positive. Table S2 displays the results for this group of medium-complexity 
samples.
The final group of samples, the high-complexity group (n  41), grew a pathogen 
that is present on the LRT panel in addition to OPF or a nonpanel pathogen. Unyvero 
detected LRT panel targets considered true positives (n  53) and targets considered 
false positives (n  6) in 38 samples. Of the six false positives, three detections were 
considered true positives based on sequencing results. The sample positive for P. 
jirovecii was negative by discrepant analysis, and for the two other false-positive 
detections (Haemophilus influenzae and Escherichia coli), discrepant analysis was not 
performed. Of the 41 samples in this group, the remaining 3 had three false-negative 
detections, and sequencing confirmed the presence of the organisms in all three 
samples. Results for the high-complexity group of samples are presented in Table S3.
Tables 2 and 3 present the cumulative pre- and post-discrepant analysis data for 
each target on the LRT panel, respectively. Positive percent agreements (PPA) were 
96.5% prior to discrepant analysis and 97.0% after discrepant analysis. Negative percent
agreements (NPA) pre- and post-discrepant analysis were 99.6% and 99.9%, respec-
tively.
Resistance genes (n 89) were detected in 52 of the 175 samples tested. Of these,
54 genes in 42 samples were attributable to a particular organism. The system cannot
differentiate which organism has the resistance gene if there is more than one
pathogen present. Resistance genes were attributable to a particular organism when
one or more resistance genes were detected in the presence of only one organism
detection. Only 18 genes belonged to isolates that underwent phenotypic AST. Results
TABLE 2 Cumulative agreement pre-discrepant analysis for all analyzed samplesa
Organism
No. of samples
% positive
agreement
% negative
agreementTP FP TN FN NA
S. aureus 34 2 135 3 1 91.9 98.5
S. pneumoniae 10 1 162 1 1 90.9 99.4
C. freundii 3 0 172 0 0 100 100
E. coli 2 3 165 0 5 100 98.2
E. cloacae complex 2 0 169 2 2 50.0 100
Proteus spp. 1 3 169 0 2 100 98.3
K. pneumoniae 10 0 164 0 1 100 100
K. oxytoca 0 0 175 0 0 NA 100
K. variicola 1 0 174 0 0 100 100
S. marcescens 10 0 165 0 0 100 100
M. morganii 0 0 175 0 0 NA 100
M. catarrhalis 6 1 164 0 4 100 99.4
P. aeruginosa 33 0 140 0 2 100 100
A. baumannii complex 13 1 161 0 0 100 99.4
S. maltophilia 26 0 147 0 2 100 100
L. pneumophila 2 0 173 0 0 100 100
P. jirovecii 1 1 173 0 0 100 99.4
H. influenzae 13 2 158 0 2 100 98.8
M. pneumoniae 0 0 175 0 0 NA 100
C. pneumoniae 0 0 175 0 0 NA 100
Total 167 14 3,291 6 22 96.5 99.6
an 175. TP, true positive; FP, false positive; TN, true negative; FN, false negative; NA, not analyzable.
TABLE 3 Cumulative agreement post-discrepant analysis for all analyzed samplesa
Organism
No. of samples
% positive
agreement
% negative
agreementTP FP TN FN NA
S. aureus 36 1 135 3 0 92.3 99.3
S. pneumoniae 12 0 162 1 0 92.3 100
C. freundii 3 0 172 0 0 100 100
E. coli 6 1 165 0 3 100 99.4
E. cloacae complex 4 0 169 2 0 66.7 100
Proteus spp. 5 0 169 0 1 100 100
K. pneumoniae 11 0 164 0 0 100 100
K. oxytoca 0 0 175 0 0 NA 100
K. variicola 1 0 174 0 0 100 100
S. marcescens 10 0 165 0 0 100 100
M. morganii 0 0 175 0 0 NA 100
M. catarrhalis 10 0 164 0 1 100 100
P. aeruginosa 35 0 140 0 0 100 100
A. baumannii complex 14 0 161 0 0 100 100
S. maltophilia 26 0 147 0 2 100 100
L. pneumophila 2 0 173 0 0 100 100
P. jirovecii 1 1 173 0 0 100 99.4
H. influenzae 15 1 158 0 1 100 99.4
M. pneumoniae 0 0 175 0 0 NA 100
C. pneumoniae 0 0 175 0 0 NA 100
Total 191 4 3,291 6 8 97.0 99.9
an 175. TP, true positive; FP, false positive; TN, true negative; FN, false negative; NA, not analyzable.
TABLE 4 Resistance genes attributable to an organism with phenotypic AST resultsa
Organism
Unyvero resistance
gene detected Phenotypic AST result(s) (n)
S. aureus mecA Oxacillin resistant (6), ND (7)
E. coli gyrAA83/gyrA87 ND (10)
blaTEM Ampicillin resistant (1), ND (4)
sul-1 ND (2)
K. pneumoniae blaTEM and blaSHV Ampicillin resistant (2)
blaCTX-M ND (1)
sul-1 ND (1)
K. variicola blaSHV Ampicillin resistant (1)
P. aeruginosa gyrA83/gyrA87 Ciprofloxacin susceptible (4), ciprofloxacin
intermediate (1), levofloxacin resistant (2),
ND (4)
A. baumannii complex blaTEM ND (1)
Proteus sp. blaTEM ND (1)
blaSHV ND (1)
H. influenzae blaTEM ND (4), ampicillin resistant (1)
aND, not done; AST, antimicrobial susceptibility testing.
are shown in Table 4. When samples were able to be analyzed, detections were largely 
concordant. The only discrepancies involved detections (n  4) of a fluoroquinolone 
resistance marker (gyrA) for Pseudomonas aeruginosa where culture determined the 
organism to be ciprofloxacin susceptible. Detection of gyrA was not further evaluated, 
as this target is not FDA cleared. Concordance for resistance genes able to be analyzed 
was 77.8% (14/18). In samples (n  63) where coinfections were detected either in 
culture or by Unyvero, multiple resistance genes were detected (n  17), a single 
resistance gene was detected (n  13), or no resistance genes were detected (n  33). 
The most common resistance gene detected in the coinfection group was blaTEM 
(n  16).
DISCUSSION
Our study compared results from quantitative bacterial culture to rapid results from 
the Unyvero LRT molecular panel. Our evaluation considered historical microbiologic 
data and administration of antimicrobial therapy for samples for which PCR and culture 
results were discrepant. Culture and PCR results were analyzed for 175 samples from 98 
patients; 31 patients had 1 sample tested, which may have introduced bias into the 
study cohort. Prior to sequencing analysis, the overall PPA was 96.5% and NPA was 
99.6%. If a discrepancy was present, sequencing analysis allowed us to more accurately 
assess the performance of the panel in terms of detecting microbial DNA when the 
culture was negative. Initial comparison of culture and PCR results revealed 14 false-
positive detections and 6 false negatives for bacterial targets. However, after sequenc-
ing, only four targets were considered to be false-positive detections, meaning that the 
presence of organism DNA could not be confirmed. A caveat in this analysis is that 
detection of microbial DNA, while confirming the analytic specificity of the LRT panel, 
does not equate to a positive culture result. This may reflect persistent detection of 
remnant nucleic acid after appropriate therapy.
While using convenience sampling for selecting our specimens bolstered our ability 
to analyze a wide variety of targets, the nature of the culture reporting methods limited 
our ability to analyze concordance for some targets in the samples analyzed. Although 
discrepant analysis is a flawed approach for evaluating diagnostic devices, its use 
allowed us to evaluate targets that were not able to be considered true or false positive 
for a variety of reasons. Nine culture results did not specify the organisms present,
(5 h from specimen collection). A shorter time to result may reduce time on inap-
propriate microbial therapy and, therefore, improve patient outcomes. Further studies
assessing outcomes and impact on clinical management are needed.
calling them mixed Gram-positive/Gram-negative organisms per routine laboratory 
protocol. However, if Unyvero detected three organisms, and the patient had a recent 
history of two of them, those two were considered true positives and the third was 
unable to be analyzed. If sequencing later confirmed the presence of the third, results 
in Table 3 reflect the assumption of a true positive. During testing, seven samples were 
completely or partially invalid and required retesting due to instrument error. Addi-
tionally, resistance data were challenging to interpret, as not all genes could be 
attributed to a particular organism and phenotypic AST was not part of routine workup 
for many isolates with resistance markers detected by LRT. Further investigation into 
resistance gene data could include a mediator resistance gene PCR. Finally, as shown 
in Tables 2 to 4, we were not able to find samples positive for all organisms and 
resistance markers on the IUO LRT panel.
The accuracy of pneumonia diagnostic testing, like all laboratory testing, relies on 
preanalytical factors. Despite the advancement of molecular technologies, the ability to 
obtain a sample that reflects the microbes present at the site of infection remains a 
barrier to accurate diagnostics (6). Further, interpretation of results has become more 
complex with the introduction of nucleic acid-based testing. A recent survey revealed 
that a majority of infectious disease physicians believe that novel diagnostics are 
becoming too complex for non-infectious disease physicians, with 79% agreeing that 
there should be stewardship in place for expensive or complicated testing (7). However, 
with appropriate stewardship and interpretation, results from molecular multiplex 
panels like LRT can provide valuable clinical information in a very critical time period
A challenge common to all nucleic acid amplification techniques is that detection 
does not imply causation. Useful to discerning true infection is a quantitative compo-
nent that is common to many bacterial culture methods (6). It has been noted in other 
evaluations of this assay that the detection of a pathogen not isolated in culture could 
represent colonization and not infection (8). Further, viable organisms cannot be 
differentiated from nonviable ones, for example, those that have been successfully 
treated with antimicrobials (9). Due to the high analytical sensitivity, some pathogens 
can be found incidentally among control subjects. In our study, we observed very high 
correlation between the LRT panel and quantitative bacterial culture of BALF. For many 
molecular tests, improved sensitivity is countered by a decrease in clinical specificity, 
but this does not appear to be true for the LRT panel.
This is the first study to describe the performance characteristics of the Unyvero LRT 
assay. Previous studies described the performance of the precursor versions P50 and 
P55. Although the LRT and P50/P55 are based on the same biochemical principle, they 
cannot directly be compared to each other due to reporting differences, such as 
unmasked reporting of resistance genes independent of detection an associated host 
organism in P50/P55. Papan et al. reported an overall sensitivity of 73.1% and a 
specificity of 97.9% for P50 compared to culture of LRT samples from pediatric or 
neonate patients. Regarding detection of resistance genes, 75% concordance with an 
antibiogram was observed where a culture counterpart was available (10). Gadsby et al. 
found an overall sensitivity/specificity of 56.9/63.2% and a sensitivity/specificity for 
antibiotic resistance detection of 18.8/94.9% for P55 (11). Ozongwu et al. reported that 
P55 detected more antimicrobial resistance markers than routine culture and assumed 
that some instances of phenotypic resistance were missed (12). Microbiology is still 
challenged by a lack of full understanding of the genetic basis of antimicrobial 
resistance. While phenotypic AST is susceptible to inconsistencies and errors, it has 
been argued that in order to accurately develop and challenge new molecular resis-
tance testing, we must maintain current methods while striving for consistency in 
newer technology (13).
The same principle can be applied to bacterial targets. Not every pathogen that can 
cause pneumonia can be covered by syndromic panels, which means that culture is still
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